Vinorelbine
| Clinical data | |
|---|---|
| Trade names | Navelbine |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a695013 |
| Pregnancy category |
|
| Routes of administration | intravenous, by mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 43 ± 14% (oral) |
| Protein binding | 79 to 91% |
| Metabolism | liver (CYP3A4-mediated) |
| Elimination half-life | 27.7 to 43.6 hours |
| Excretion | Fecal (46%) and kidney (18%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C45H54N4O8 |
| Molar mass | 778.947 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (what is this?) (verify) | |
Vinorelbine, sold under the brand name Navelbine among others, is a chemotherapy medication used to treat a number of types of cancer. This includes breast cancer and non-small cell lung cancer. It is given by injection into a vein or by mouth.
Common side effects include bone marrow suppression, pain at the site of injection, vomiting, feeling tired, numbness, and diarrhea. Other serious side effects include shortness of breath. Use during pregnancy may harm the baby. Vinorelbine is in the vinca alkaloid family of medications. It is believed to work by disrupting the normal function of microtubules and thereby stopping cell division.
Vinorelbine was approved for medical use in the United States in 1994. It is on the World Health Organization's List of Essential Medicines.